copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Clinical effectiveness of fresh frozen plasma compared with fibrinogen . . . Introduction Haemostatic therapy in surgical and or massive trauma patients typically involves transfusion of fresh frozen plasma (FFP) Purified human fibrinogen concentrate may offer an alternative to FFP in some instances In this systematic review, we investigated the current evidence for the use of FFP and fibrinogen concentrate in the perioperative or massive trauma setting Methods
A national study of plasma use in critical care: clinical indications . . . Introduction Fresh frozen plasma (FFP) is widely used, but few studies have described patterns of plasma use in critical care We carried out a multicentre study of coagulopathy in intensive care units (ICUs) and here describe overall FFP utilisation in adult critical care, the indications for transfusions, factors indicating the doses used and the effects of FFP use on coagulation Methods We
Balanced massive transfusion ratios in multiple injury patients with . . . Introduction Retrospective studies have demonstrated a potential survival benefit from transfusion strategies using an early and more balanced ratio between fresh frozen plasma (FFP) concentration and packed red blood cell (pRBC) transfusions in patients with acute traumatic coagulopathy requiring massive transfusions These results have mostly been derived from non-head-injured patients The
Therapeutic target of high fresh frozen plasma to red blood cell ratio . . . Abstract Background To assess heterogeneous treatment effects of high fresh frozen plasma (FFP) to red blood cell (RBC) transfusion ratios in patients with severe blunt trauma and to identify subgroups that derive the greatest survival benefit
Prothrombin complex concentrate versus fresh frozen plasma in patients . . . To reverse oral anticoagulant (OAC) therapy, a number of treatment modalities is available Fresh frozen plasma (FFP) is effective and is currently used for coagulation factor replacement, carrying a risk of volume overload, transmission of infective agents and being time consuming Variable and frequently low potency of clotting factors results in minor haemostatic effects compared with
The effect of male-donor-only fresh frozen plasma on the incidence of . . . Transfusion-related acute lung injury, due to plasma from female donors containing antileucocyte antibodies, may be a common contributor to the development of acute lung injury (ALI) in the critically ill In July 2003 the English Blood Service stopped using female donor plasma for the manufacture of fresh frozen plasma (FFP) Patients undergoing repair of ruptured abdominal aortic aneurysm
The European guideline on management of major bleeding and coagulopathy . . . Background Severe traumatic injury continues to present challenges to healthcare systems around the world, and post-traumatic bleeding remains a leading cause of potentially preventable death among injured patients Now in its fifth edition, this document aims to provide guidance on the management of major bleeding and coagulopathy following traumatic injury and encourages adaptation of the
Pre-hospital plasma transfusion: a valuable coagulation support or an . . . Moreover, the INR of FFP is 1 3 [6] Any beneficial effect of plasma to correct slightly elevated INR is futile and plasma has primarily an effect on coagulation parameters with extended volumes and performs best in patients bleeding and coagulopathic
Critical appraisal and concerns regarding a meta-analysis on . . . FFP has low doses of fibrinogen, posing challenges in maintaining fibrinogen blood concentration with plasma alone during resuscitation Additionally, while the other studies in the meta-analysis excluded patients on anticoagulation, the authors explicitly state that it was not a criterion of exclusion
Comparison of published guidelines for management of coagulopathy and . . . Critically ill patients with COVID-19 are at increased risk for thrombotic complications which has led to an intense debate surrounding their anticoagulation management In the absence of data from randomized controlled clinical trials, a number of consensus guidelines and recommendations have been published to facilitate clinical decision-making on this issue However, substantive differences